NCT04153201View on ClinicalTrials.gov

Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 15, 2013

Primary Completion Date

October 1, 2019

Study Completion Date

October 16, 2019

Conditions
Antiphospholipid Syndrome
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine 200 mg daily for patients weighing \< 60 kg, hydroxychloroquine 400 mg daily for patients weighing \>= 60 kg

Trial Locations (1)

11527

Laikon General Hospital, Athens

All Listed Sponsors
lead

National and Kapodistrian University of Athens

OTHER

NCT04153201 - Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome | Biotech Hunter | Biotech Hunter